The FDA’s accelerated approval process, which allows pharmaceutical companies to license treatments without proving they are effective, has become a common path to market — accounting for 14 of the 50 approvals of novel drugs in 2021 compared with four among 59 in 2018: https://khn.org/news/article/pharma-fda-drugs-accelerated-approval-marginally-effective-expensive/